HELP
NASDAQ HealthcareCybin Inc. - Common Stock
Biotechnology
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
๐ Market Data
| Price | $7.04 |
|---|---|
| Volume | 3,777,187 |
| Market Cap | 436.37M |
| Beta | 0.620 |
| RSI (14-Day) | 63.7 |
| 200-Day MA | $6.00 |
| 50-Day MA | $5.17 |
| 52-Week High | $9.12 |
| 52-Week Low | $3.76 |
| Forward P/E | -3.00 |
| Price / Book | 134.63 |
๐ฏ Investment Strategy Scores
HELP scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (69/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (10/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find HELP in your text
Paste any article, transcript, or post โ the tool will extract HELP and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.